Celsus Therapeutics will acquire Volution Immuno Pharmaceuticals (VIP), creating a combined company focused on developing and commercializing treatments for orphan autoimmune and inflammatory diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results